Publications
Find an abstract and a link to most of the publications produced by Nordic Bioscience
Rheumatoid arthritis (RA) is a chronic inflammatory disease with fluctuating course of progression. Despite substantial improvement in treatments in recent years, treatment response is still not guaranteed. The aim of this study was to identify variation in Disease Activity Score 28 (DAS28) of RA pa...
August 18, 2020
Journal:
Sci Rep
Author:
Blair JPM, Bay-Jensen AC, Thang MH, Frederiksen P, Karsdal MA, Brunak S, Bager CL
Local inflammation in axial spondyloarthritis (axSpA) leads to the release of collagen metabolites from the disease-affected tissue. We investigated whether collagen metabolites were associated with disease activity and could distinguish non-radiographic(nr)-axSpA from ankylosing spondylitis (AS). A...
August 2, 2019
Journal:
Sci Rep
Author:
Husakova M, Bay-Jensen AC, Zegzulkova K, Tomcik M, Bubová K, Horínková J, Gatterová J, Pavelka K, Siebuhr AS, Forejtová S, Gregová S
There is an increasing demand for accurate endotyping of patients according to their pathogenesis to allow more targeted treatment. We explore a combination of blood-based joint tissue metabolites (neoepitopes) to enable patient clustering through distinct disease profiles. We analysed data from two...
BACKGROUND: Osteoarthritis (OA) leads to joint failure and total joint replacement (TJR, either hip (H) or knee (K)). Worsening of pain and joint space narrowing are believed to be surrogates for joint failure; however, we hypothesize that TJR, as a reflection of joint failure, can be used as an end...
June 26, 2019
Journal:
BMC Musculoskelet Disord
Author:
Bager CL, Karsdal MA, Thudium CS, Byrjalsen I, Bay-Jensen AC, Bihlet AR
OBJECTIVES: Pain and disability are the main clinical manifestations of osteoarthritis, for which only symptomatic therapies are available. Hence, there is a need for therapies that can simultaneously alter disease progression and provide pain relief. KBP is a dual amylin- and calcitonin-receptor ag...
June 5, 2019
Journal:
Osteoarthritis Cartilage
Author:
Katri A, Dabrowska A, Karsdal MA, Andreassen KV, Thudium CS, Henriksen K, Löfvall H
OBJECTIVE: The objective was to investigate blood-based biomarkers of type I (PRO-C1), III (PRO-C3) and VI (PRO-C6) collagen formation in systemic sclerosis (SSc) patients and examine their correlation to modified Rodnan skin score (mRSS). METHODS: Limited (lSSc, n = 76) and diffuse SSc (dSSc, n = 4...
March 1, 2019
Journal:
Biomarkers
Author:
Juhl P, Vinderslev Iversen L, Karlsmark T, Karsdal MA, Bay-Jensen AC, Mogensen M, Siebuhr AS
C-telopeptide of type II collagen (CTX-II) has been shown to be a highly relevant biomarker of cartilage degradation in human rheumatic diseases, if measured in synovial fluid or urine. However, serum or plasma CTX-II have not been demonstrated to have any clinical utility to date. Here, we describe...
February 28, 2019
Journal:
Sci Rep
Author:
Löfvall H, Katri A, Dabrowska A, Karsdal MA, Luo Y, He Y, Manon-Jensen T, Dziegiel MH, Bay-Jensen AC, Thudium CS, Henriksen K
BACKGROUND: Pain is a debilitating symptom of rheumatoid arthritis (RA), caused by joint inflammation and cartilage and bone destruction. Nonsteroidal anti-inflammatory drugs (NSAIDs) are used to treat pain and inflammation in RA, but are not disease-modifying and do not prevent joint destruction wh...
February 22, 2019
Journal:
Arthritis Res Ther
Author:
Katri A, Dabrowska A, Löfvall H, Ding M, Karsdal MA, Andreassen KV, Henriksen K, Thudium CS
OBJECTIVES: Non-radiographic (nr-axSpA) and radiographic (AS) forms of axial spondyloarthritis (axSpA) share clinical features, but have different radiographic patterns. Radiographic progression is not associated with the current disease activity biomarkers. We investigated a matrix metalloproteinas...
February 11, 2019
Journal:
Clin Exp Rheumatol
Author:
Siebuhr AS, Husakova M, Zegzulkova K, Tomcik M, Urbanova M, Grobelna K, Gatterova J, Bay-Jensen AC, Pavelka K, Forejtová S
PURPOSE OF REVIEW: This review focuses on the molecular taxonomy of osteoarthritis from the perspective of molecular biomarkers. We discuss how wet biochemical markers may be used to understand disease pathogenesis and progression and define molecular endotypes of osteoarthritis and how these corres...
January 31, 2019
Journal:
Curr Opin Rheumatol
Author:
mobasheri A, Van Spil WE, Budd E, Uzieliene I, Bernotiene E, Bay-Jensen AC, Larkin J, Levesque MC, Gualillo O, Henrotin Y
OBJECTIVE: Phenotypic changes of chondrocytes toward hypertrophy might be fundamental in the pathogenesis of OA, of which type X collagen (Col10) is a well-known marker. The purpose was to develop a specific immunoassay for blood quantification of a newly identified neo-epitope of type X collagen to...
January 14, 2019
Journal:
Osteoarthritis Cartilage
Author:
He Y, Manon-Jensen T, Arendt-Nielsen L, Petersen KK, Christiansen T, Samuels J, Karsdal MA, Attur M, Bay-Jensen AC, Abramson SB
There is a need for efficacious and safe pain treatments for OA (osteoarthritis). The nerve growth factor (NGF) antibody tanezumab is associated with high efficacy, but when combined with chronic NSAID treatment shows an increased risk of rapidly progressive osteoarthritis (RPOA) in a small group of...
December 18, 2018
Journal:
Osteoarthritis Cartilage
Author:
Karsdal MA, Verburg KM, West CR, Bay-Jensen AC
BACKGROUND: Systemic sclerosis (SSc) is characterized by excessive fibrosis throughout the body. This leads to the release of extracellular matrix (ECM) fragments into circulation, where they may be quantified as biomarkers. The objectives were to investigate levels of ECM turnover biomarkers and th...
December 3, 2018
Journal:
PLoS One
Author:
Juhl P, Bay-Jensen AC, Karsdal MA, Siebuhr AS, Franchimont N, Chavez JC
PURPOSE: Extracellular matrix (ECM) deposition and remodelling in skin and lungs of systemic sclerosis (SSc) subjects lead to release of metabolites/biomarkers into circulation. We investigated if biomarkers of ECM degradation (biglycan and elastin) and macrophage activation (citrullinated vimentin)...
November 20, 2018
Journal:
Biomarkers
Author:
Siebuhr AS, Juhl P, Bay-Jensen AC, Karsdal MA, Franchimont N, Chavez JC
In 1992, the Food and Drug Administration (FDA) instituted the accelerated approval regulations that allow drugs or biologics for serious conditions that fill an unmet medical need to be approved on the basis of a surrogate endpoint or an intermediate clinical endpoint. The current definition of a s...
November 19, 2018
Journal:
Osteoarthritis Cartilage.
Author:
Kraus VB, Simon LS, Katz JN, Neogi T, Guermazi A, Karsdal MA, Hunter DJ
OBJECTIVES: Macrophages possess widespread pro-inflammatory, destructive, and remodelling capabilities that can critically contribute to acute and chronic diseases, such as rheumatoid arthritis (RA). Continuous monitoring and measurement of selective counteraction of macrophage activity in patients ...
November 7, 2018
Journal:
Clin Exp Rheumatol.
Author:
Mortensen JH, Guo X, De Los Reyes M, Dziegiel MH, Bay Jensen AC, White WI
N-terminal propeptide of type II collagen (PIINP) is a biomarker reflecting cartilage formation. PIINP exists in two main splice variants termed as type IIA and type IIB collagen NH₂-propeptide (PIIANP, PIIBNP). PIIANP has been widely recognized as a cartilage formation biomarker. However, the utili...
November 6, 2018
Journal:
Int J Mol Sci
Author:
Luo Y, He Y, Gudmann NS, Henriksen K, Simonsen O, Ladel C, Mobasheri A, Karsdal MA, Bay-Jensen AC, Michaelis M
OBJECTIVE: A hallmark of osteoarthritis (OA) is degradation of articular cartilage proteoglycans. In isolated human OA chondrocytes, the anti-inflammatory cytokine Interleukin-37 (IL-37) lowers the expression of the proteolytic MMP and ADAMTS enzymes, which mediate this degradation. Therefore, we in...
September 7, 2018
Journal:
Osteoarthritis Cartilage
Author:
Van Geffen EW, Van Caam APM, Van de Loo FA, Van Lent PLEM, Koenders MI, Thudium CS, Bay-Jensen AC, Blaney Davidson EN, Van der Kraan PM
OBJECTIVE: Currently, there are no disease-modifying osteoarthritis drugs (DMOADs) approved for osteoarthritis. It is hypothesized that a subtype of OA may be driven by inflammation and may benefit from treatment with anti-inflammatory small molecule inhibitors adopted from treatments of rheumatoid ...
July 29, 2018
Journal:
Biochem Pharmacol
Author:
Kjelgaard-Petersen CF, Sharma N, Kayed A, Karsdal MA, Mobasheri A, Hägglund P, Bay-Jensen AC, Thudium CS
BACKGROUND: Radiographic axial spondyloarthritis (r-axSpA) is associated with extracellular matrix (ECM) remodelling of affected tissues. We investigated whether there was a relationship between biomarkers of ECM remodelling and 2-year radiographic progression in r-axSpA. METHODS: Patients from the...
May 14, 2018
Journal:
RMD open
Author:
Siebuhr AS, van de Heijde D, Bay-Jensen AC, Karsdal MA, Landewé R, van Tubergen A, Ramiro S
OBJECTIVES: The expanding spectrum of targeted therapies for rheumatoid arthritis (RA) implies a need for development of precision tools for disease assessment reflecting pathobiologic processes. Type IV collagen is an abundant protein of basement membranes, but is also present in the intercellular ...
May 8, 2018
Journal:
Clin Exp Rheumatol
Author:
Gudmann NS, Junker P, Juhl P, Thudium CS, Siebuhr AS, Byrjalsen I, Karsdal MA, Bay-Jensen AC
There is a lack of biochemical markers for non-invasive and objective assessment of symptomatic osteoarthritis (OA). Aggrecanase activity has been shown to be associated with joint deterioration and symptomatic disease through the degradation of extracellular matrix proteins, such as type III collag...
April 25, 2018
Journal:
Clin Biochem
Author:
Bay-Jensen AC, Kjelgaard-Petersen CF, Petersen KK, Arendt-Nielsen L, Quasnichka HL, Mobasheri A, Karsdal MA, Leeming DJ
Osteoarthritis (OA) is the most common arthritic disease in the world, leading to debilitating pain and destruction of joint tissues. While pain is the hallmark symptom of osteoarthritis, clear associations between pain and disease processes involved in joint deterioration are lacking. OA pain is mu...
April 25, 2018
Journal:
J Proteomics
Author:
Thudium CS, Löfvall H, Karsdal MA, Bay-Jensen AC, Bihlet AR
OBJECTIVE: Rheumatoid arthritis (RA) is a chronic, autoimmune and degenerative joint disease leading to disability, reduced life quality, and increased mortality. Although several synthetic and biological disease modifying anti-rheumatic drugs (DMARDs) are available, there is still a medical need fo...
April 18, 2018
Journal:
Arthritis Rheumatol
Author:
Kjelgaard-Petersen CF, Platt A, Braddock M, Jenkins MA, Musa K, Graham E, Gantzel T, Slynn G, Weinblatt ME, Karsdal MA, Thudium CS, Bay-Jensen AC
OBJECTIVES: This prospective study aimed to use serological biomarkers for evaluation of, connective tissue turnover, in a population of 149 Japanese patients with rheumatoid arthritis (RA). It was aimed to investigate how the connective tissue was affected by treatment at follow-up after 1 year (+/...
February 14, 2018
Journal:
Clin Exp Rheumatol
Author:
Gudmann NS, Hirata S, Karsdal MA, Kubo S, Bay-Jensen AC, Tanaka Y
OBJECTIVES: The objective of this study was to examine the tissue degradation in response to anti-IL6 receptor treatment in rheumatoid arthritis (RA) patients which are anti-TNF-α inadequate responders. METHODS: RADIATE was a randomised, double-blinded, placebo-controlled, parallel-group, phase III...
January 31, 2018
Journal:
Clin Exp Rheumatol
Author:
Juhl P, Thudium CS, Gudmann NS, Karsdal MA, Bay-Jensen AC, Siebuhr AS
Objective Gender is a risk factor in the onset of osteoarthritis (OA). The aim of the study was to investigate gender differences in contact area (CA) and congruity index (CI) in the medial tibiofemoral (MTF) joint in 2 different cohorts, quantified automatically from magnetic resonance imaging (MRI...
BACKGROUND: Sprifermin (recombinant human fibroblast growth factor 18) is in clinical development as a potential disease-modifying osteoarthritis drug (DMOAD). In vitro studies have shown that cartilage regenerative properties of sprifermin involve chondrocyte proliferation and extracellular matrix ...
December 12, 2017
Journal:
J Transl Med
Author:
Reker D, Kjelgaard-Petersen CF, Siebuhr AS, Michaelis M, Gigout A, Karsdal MA, Ladel C, Bay-Jensen AC
OBJECTIVES:Targeting the granulocyte-macrophage colony-stimulating factor (GM-CSF) pathway holds great potential in the treatment of inflammatory diseases. Mavrilimumab, a human monoclonal GM-CSF receptor-α antibody, has demonstrated clinical efficacy in RA. Our current study aimed to elucidate mech...
October 23, 2017
Journal:
Rheumatology (Oxford)
Author:
Guo X, Higgs BW, Bay-Jensen AC, Wu Y, Karsdal MA, Kuziora M, Godwood A, Close D, Ryan PC, Roskos LK, White WI
PURPOSE OF REVIEW:There is an increasing demand for noninvasive and descriptive biochemical markers (biomarkers) in osteoarthritis; for enabling early drug development (including translational research), evaluating clinical trial at an early stage and for subtyping. Purpose of the review is to revie...
Search and find publications that we have published.
Please don't hesitate to contact us if you have any questions or other inquiries.
